Pharmacy volume versus HS 30 imports
Pharmacy sales are a retail reference and are not added to imports. Costa Rica’s HS 30 figure exceeds pharmacy sales because of hospital, industrial, and re-export flows.
Commercial Intelligence
For Manufacturers
Commercial and tender intelligence for manufacturers and distributors entering or growing in Central America.
Pharmacy volume
Hover over a country to see its pharmacy volume and imports.Tap a country to see its pharmacy volume and imports.
LowerHigher
Market Volume
Central America and the Dominican Republic form a multi-billion-dollar pharmaceutical bloc. Pharmacy sales and HS 30 imports are separate lenses on scale: one is retail-channel volume, the other is a partial trade basket that includes hospital, industrial, and re-export flows.
Pharmacy volume
US$4.85B
Mar 2024 · +6.6% YoY
HS 30 pharma imports
US$6.02B
SE-COMISCA medicines basket — not retail sales
Audited total market
US$6.02B
CADR retail + non-retail (~USD$6.02B)
India share of HS 30
7.0%
US$419.5M of the USD$6.02B import basket
Pharmacy sales are a retail reference and are not added to imports. Costa Rica’s HS 30 figure exceeds pharmacy sales because of hospital, industrial, and re-export flows.
India HS 30 is importer-reported value as a share of the SE-COMISCA medicines basket. China HS 30 is reported where a Comtrade figure exists; pale bars are 2023 top-10 ceilings. China HS 9018 is the medical-instruments share.
Weighted China share is 11.2% (US$149.9M of US$1.34B). Dominican Republic leads at 30.1%; Costa Rica is only 4.2% despite the largest instrument import bill.
Values in US$ millions except percentages. India and China HS 30 shares use importer-reported Comtrade; volume columns use the regional briefing table.
| Country | Pharmacy | YoY | HS 30 | India HS 30 | China HS 30 | HS 9018 | China HS 9018 |
|---|---|---|---|---|---|---|---|
| Dominican RepublicPROMESE/CAL and SNS | US$1.14B | -2.0% | US$1.01B | US$102.0M | Below top 10 | US$114.3M | US$34.4M |
| GuatemalaMSPAS and IGSS | US$968M | +9.3% | US$1.12B | US$115.0M | US$27.0M | US$122.0M | US$29.4M |
| Costa RicaCCSS | US$731M | +16.3% | US$1.11B | US$31.0M | US$21.8M | US$779.7M | US$32.7M |
| HondurasSESAL and IHSS | US$665M | +9.3% | US$757.0M | US$43.0M | Below top 10 | US$40.3M | US$11.2M |
| El SalvadorMINSAL and ISSS | US$496M | +7.1% | US$646.5M | US$39.0M | Below top 10 | US$76.4M | US$18.5M |
| PanamaMINSA and CSS | US$486M | +3.4% | US$824.3M | US$22.5M | Below top 10 | US$138.6M | US$11.6M |
| NicaraguaMINSA | US$358M | +9.6% | US$550.7M | US$67.0M | US$23.3M | US$66.4M | US$12.4M |
| SE-COMISCA | US$4.85B | +6.6% | US$6.02B | US$419.5M | Reported in GT, CR, NI | US$1.34B | US$149.9M · 11.2% |
Belize is a COMISCA member but is omitted from the source import table. HS 30 and HS 9018 are partial baskets. Gross imports are not accessible demand for any single origin. Sources: SE-COMISCA import briefing, UN Comtrade HS 30.
Market Opportunity
The Central American pharmaceutical market is fragmented across four national procurement systems: Costa Rica's SICOP, Guatemala's Guatecompras, Panama's PanamaCompra, and Honduras's Sistema de Compras Públicas. Today, these systems operate in silos. Suppliers are forced to monitor each platform manually, creating delays, missed opportunities, and lost market share. Tendrium centralizes pharmaceutical and medical procurement across these markets in a single, real-time intelligence platform. You don't hunt for tenders — they find you.
The Market Gap
Each Central American country publishes public procurement data, but no unified access exists
Manual monitoring creates days of lag; competitors with automated systems move first
Procurement systems publish raw lists; they don't surface competitive intelligence, price trends, or institutional buying patterns
2,400+ tenders monthly in Costa Rica alone; 8,000+ across Central America — impossible to monitor manually
Why Now
Core Capabilities
Business Outcomes
25–40%
Modeled potential win-rate lift — not a guaranteed result
15–20h
Illustrative weekly hours saved per sales team
±5%
Modeled margin stability per bid
30–50%
Modeled revenue potential from expansion — not a guaranteed result